40Hz tACS in Treating Cognitive Function and Modulating Neurophysiology of Patients With Alzheimer's Disease
NCT ID: NCT05723172
Last Updated: 2023-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
48 participants
INTERVENTIONAL
2023-09-01
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transcranial Alternating Current Stimulation Combined With 40Hz Sound Stimulation for Treatment Alzheimer's Disease
NCT05251649
40 Hz Transcranial Alternating Current Stimulation for Inducing Gamma Oscillations
NCT06740864
Investigating Different Frequencies of Transcranial Electrical Stimulations in Dementia Population
NCT06547021
Memory Enhancement Using Transcranial Alternating Current Stimulation
NCT06202872
At Home Gamma tACS in Alzheimer's Disease (tACS@Home)
NCT05643326
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
40mins 10Hz-tACS for daily consecutive sessions will be given.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
active tACS
40 mins tACS for 10 consecutive daily sessions
active tACS
40 mins tACS for 10 consecutive daily sessions
sham tACS
40 mins sham tACS for 10 consecutive daily sessions
sham tACS
40 mins sham tACS for 10 consecutive daily sessions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
active tACS
40 mins tACS for 10 consecutive daily sessions
sham tACS
40 mins sham tACS for 10 consecutive daily sessions
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* clinical dementia rating scale (CDR) of 1 or mini-mental state examination (MMSE) score of 18 to 26.
* Participants were allowed to maintain their anti-dementia medications without changes from at 3 months before and throughout the study.
Exclusion Criteria
* clinical depression measured by Hamilton depression rating scale score equal and over 17
60 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Che-Sheng Chu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Che-Sheng Chu
Attending Physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Che-Sheng Chu, MD
Role: PRINCIPAL_INVESTIGATOR
Department of Psychiatry, Kaohsiung Veterans General Hospital, Taiwan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Psychiatry, Kaohsiung Veterans General Hospital
Kaohsiung City, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ching PY, Hsu TW, Chen GW, Pan CC, Chu CS, Chou PH. Efficacy and Tolerability of Cranial Electrotherapy Stimulation in the Treatment of Anxiety: A Systemic Review and Meta-Analysis. Front Psychiatry. 2022 Jun 9;13:899040. doi: 10.3389/fpsyt.2022.899040. eCollection 2022.
Chou PH, Lin YF, Lu MK, Chang HA, Chu CS, Chang WH, Kishimoto T, Sack AT, Su KP. Personalization of Repetitive Transcranial Magnetic Stimulation for the Treatment of Major Depressive Disorder According to the Existing Psychiatric Comorbidity. Clin Psychopharmacol Neurosci. 2021 May 31;19(2):190-205. doi: 10.9758/cpn.2021.19.2.190.
Chu CS, Li CT, Brunoni AR, Yang FC, Tseng PT, Tu YK, Stubbs B, Carvalho AF, Thompson T, Rajji TK, Yeh TC, Tsai CK, Chen TY, Li DJ, Hsu CW, Wu YC, Yu CL, Liang CS. Cognitive effects and acceptability of non-invasive brain stimulation on Alzheimer's disease and mild cognitive impairment: a component network meta-analysis. J Neurol Neurosurg Psychiatry. 2021 Feb;92(2):195-203. doi: 10.1136/jnnp-2020-323870. Epub 2020 Oct 28.
Chen GW, Hsu TW, Ching PY, Pan CC, Chou PH, Chu CS. Efficacy and Tolerability of Repetitive Transcranial Magnetic Stimulation on Suicidal Ideation: A Systemic Review and Meta-Analysis. Front Psychiatry. 2022 May 6;13:884390. doi: 10.3389/fpsyt.2022.884390. eCollection 2022.
Hung YY, Yang LH, Stubbs B, Li DJ, Tseng PT, Yeh TC, Chen TY, Liang CS, Chu CS. Efficacy and tolerability of deep transcranial magnetic stimulation for treatment-resistant depression: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Apr 20;99:109850. doi: 10.1016/j.pnpbp.2019.109850. Epub 2019 Dec 19.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VGHKS-112-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.